Literature DB >> 22067186

Prevalence and pathophysiology of functional constipation among women in Catalonia, Spain.

Yolanda Ribas1, Esther Saldaña, Joan Martí-Ragué, Pere Clavé.   

Abstract

BACKGROUND: Specific treatment of functional bowel disorders requires precise diagnosis. However, prevalence and subtypes of functional constipation among women are not completely understood.
OBJECTIVE: Our aim was to assess the prevalence of functional constipation and investigate the subtypes of dyssynergic defecation and slow transit constipation among Spanish women.
DESIGN: We performed a prospective epidemiological study in healthy young women and retrospective pathophysiological studies in 2 patient cohorts of women with functional constipation according to Rome II criteria. SETTINGS: Referral centers at Clínica Sagrada Familia, Barcelona, Spain, and Hospital de Mataró, Mataró, Spain. PATIENTS: The epidemiological study included 600 healthy young women, aged 37.1 (SD, 8.2) years. Patient cohort 1 comprised 172 women with functional constipation without symptoms of pelvic floor dysfunction, ranging in age from 18 to 45 years. Patient cohort 2 comprised 106 women with functional constipation and symptoms of dyssynergic defecation, ranging in age from 45 to 65 years. MAIN OUTCOME MEASURES: In healthy women, a questionnaire was used to determine rates of functional constipation, dyssynergic defecation, and slow transit constipation. In patients, results of anorectal manometry, EMG, and colonic transit studies were reviewed to assess subtypes of functional constipation; in addition, results of dynamic videoproctography were reviewed in cohort 2 to assess the role of structural pelvic floor disorders.
RESULTS: The prevalence of functional constipation in healthy young women was 28.8%; symptoms of dyssynergic defecation were found in 8.2%, those of isolated slow transit in only 0.17%. In patient cohort 1, a total of 143 patients (83.1%) showed dyssynergic defecation: 117 patients (68.0%) had paradoxical external anal sphincter contraction and 26 (15.1%) had impaired internal anal sphincter relaxation). Slow transit constipation without dyssynergia was observed in 15 (8.7%). Up to 40.2% of patients with dyssynergia also had delayed colonic transit. In the cohort of 106 women with dyssynergic defecation, videoproctography showed impaired puborectal relaxation in 64 patients (60.4%), anterior rectocele in 65 (61.3%), and rectal prolapse in 13 (12.3%). LIMITATIONS: We could not estimate the prevalence and subtypes of irritable bowel syndrome in the epidemiological study.
CONCLUSIONS: Functional constipation is extremely prevalent among young, healthy, Spanish women, dyssynergic defecation being the most prevalent subtype. Slow transit constipation without dyssynergic defecation is uncommon. Structural pelvic floor disorders are highly prevalent in middle-aged women with dyssynergic defecation.

Entities:  

Mesh:

Year:  2011        PMID: 22067186     DOI: 10.1097/DCR.0b013e31822cb5c2

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

1.  Comparison of laparoscopic subtotal colectomy with posterior vaginal suspension and laparoscopic subtotal colectomy with transvaginal repair for patients with slow-transit constipation complicated with rectocele: a non-randomized comparative study in a single center.

Authors:  Si Yu; Jian-Zhong Deng; Xiang Peng; Yong-Hui Zhou; Long-Qing Cheng; Yi-Ban Lin; Jia-Cheng Zhu; Te-Dong Luo
Journal:  Surg Endosc       Date:  2015-10-20       Impact factor: 4.584

2.  Clinical and investigative assessment of constipation: a study from a referral center in western India.

Authors:  Nimish Shah; Rajiv Baijal; Praveen Kumar; Deepak Gupta; Sandeep Kulkarni; Soham Doshi; Deepak Amarapurkar
Journal:  Indian J Gastroenterol       Date:  2014-10-15

3.  Constipation Risk in Patients Undergoing Abdominal Surgery.

Authors:  Sevim Celik; Nurdan Yalcin Atar; Nilgun Ozturk; Guler Mendes; Figen Kuytak; Esra Bakar; Duygu Dalgiran; Sumeyra Ergin
Journal:  Iran Red Crescent Med J       Date:  2015-06-23       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.